Early breast cancer: ASCO adds MammaPrint to guideline

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • The MammaPrint genomic assay is best used to guide systemic therapy decisions in 2 groups of patients with early breast cancer: 1) hormone receptor (HR)-positive/human epidermal growth factor receptor (HER2)-negative, node-negative patients with high clinical risk; and 2) HR+/HER2...